SCHEMBL3049166

SCHEMBL3049166

COc1cccc(OC2CCN(c3nncc4c(OC)c(OC)c(OC)cc34)CC2)c1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GPR6 P46095 2/20 0.45
PDE3B Q13370 11/20 0.44
PDE3A Q14432 11/20 0.44
PDE10A Q9Y233 10/20 0.44
KMT2A Q03164 2/20 0.40
LMNA P02545 1/20 0.40
FPR2 P25090 1/20 0.39
PROKR1 Q8TCW9 1/20 0.39
C1S P09871 1/20 0.39
SLC6A2 P23975 1/20 0.38
SLC6A4 P31645 1/20 0.38
SLC6A3 Q01959 1/20 0.38
TGFBR1 P36897 1/20 0.38
ACVR1 Q04771 1/20 0.38
MAOB P27338 1/20 0.37
HTR6 P50406 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3055244 0.92 PDE3B (0.41) GPR6PDE3BPDE3APDE10AKMT2A
SCHEMBL3053175 0.92 LMNA (0.44) GPR6PDE3BPDE3APDE10AKMT2A
SCHEMBL3062047 0.91 PDE3B (0.41) GPR6PDE3BPDE3APDE10AKMT2A
SCHEMBL3060696 0.91 TGFBR1 (0.44) GPR6PDE3BPDE3APDE10AKMT2A
SCHEMBL3052995 0.86 PDE10A (0.49) PDE3BPDE3APDE10AKMT2ALMNA
SCHEMBL3059796 0.86 PDE10A (0.49) GPR6PDE3BPDE3APDE10AKMT2A
SCHEMBL3062919 0.86 DRD2 (0.45) PDE10AKMT2ALMNAC1S
SCHEMBL3062929 0.86 CHRM4 (0.43) GPR6PDE3BPDE3APDE10AKMT2A
SCHEMBL3052978 0.84 PDE10A (0.52) PDE3BPDE3APDE10AKMT2ALMNA
SCHEMBL3057939 0.83 GPR6 (0.43) GPR6PDE3BPDE3APDE10AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100222353-A1 AMINOPHTHALAZINE DERIVATIVE COMPOUNDS PFIZER PRODUCTS INC. (US) 2010-09-02 US claimed
EP-1981868-A2 AMINOPHTHALAZINE DERIVATIVE COMPOUNDS Pfizer Products Inc. (US) 2008-10-22 EP claimed
WO-2007085954-A2 AMINOPHTHALAZINE DERIVATIVE COMPOUNDS PFIZER PRODUCTS INC. (US) 2007-08-02 WO claimed
US-20100222353-A1 AMINOPHTHALAZINE DERIVATIVE COMPOUNDS PFIZER PRODUCTS INC. (US) 2010-09-02 US disclosed
EP-1981868-A2 AMINOPHTHALAZINE DERIVATIVE COMPOUNDS Pfizer Products Inc. (US) 2008-10-22 EP disclosed
WO-2007085954-A2 AMINOPHTHALAZINE DERIVATIVE COMPOUNDS PFIZER PRODUCTS INC. (US) 2007-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222353-A1 AMINOPHTHALAZINE DERIVATIVE COMPOUNDS PDE12, PDE5A, PDE2A GPR6 2466/4885PDE3B 9/4885PDE3A 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.